Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment. by Felix L. Herr (21544362)

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Comparison of data after the experiment. by Neng Pan (5262032)

Baseline characteristics. by Neng Pan (5262032)

“…Following the intervention, the HIIT NW group exhibited a marked increase in limb lean mass, which led to a significant rise in the skeletal muscle index (SMI) (p < 0.001). …”

Data ste. by Neng Pan (5262032)

“…Following the intervention, the HIIT NW group exhibited a marked increase in limb lean mass, which led to a significant rise in the skeletal muscle index (SMI) (p < 0.001). …”

Comparison of post-experimental outcome measures. by Neng Pan (5262032)

“…Following the intervention, the HIIT NW group exhibited a marked increase in limb lean mass, which led to a significant rise in the skeletal muscle index (SMI) (p < 0.001). …”

5-HT supplementation induces mitochondrial damage. by Li Gao (131516)

Brain disintegration in <i>aP2- Drp1</i>^f/f neonatal mice. by Yuta Ibayashi (20404811)